Genmab — November 2020

E_L

2x NSCLC, Urothelial, Endometrial, TNBC (Triple-negative breast cancer), SCCHN (
Squamous Cell Carcinoma of the Head and Neck) and Cervical

peter12

Judith also mentioned CR's at the cc ?

peter12

And as disclosed in the abstract, by the time of the cut, the median follow-up was 8.3 months, and 25 patients were still ongoing. And I think that with this, I give you a signal, that 25 patients were still ongoing. And if you look at the data again at the tail, in above 48 milligrams for the DLBCL from 7 patients, the ORR was 100%; CR, 28%; 72% PRs, and those patients were ongoing. So – and the FPL, same thing, above 12. And the cut is arbitrary,

Bulder

det er epco Peter

peter12

ok tak

E_L

on P20 of the presentation , fig A, the best change in SoD from baseline =-100%; does that mean the tumor disappeared?

E_L

should we conclude that Colorectal cancer and Ovarian cancer will not continue to the expansion phase?

Bulder

looks like it, both Q

E_L

what is it then that you where hoping for / expecting?

GeorgeBest

Thanks E L for the fantastic job you are doing

gdn55

Ditto her. Tak

E_L

I did - and no need to say thanks.

E_L

but seriously curious what people where expecting/ why they are disapointed. We have seen these sort of early data sets many times before now, it ususally isn't more then this

GeorgeBest

Yes, I must admit, I got carried away with Jans words again again...;-)

GeorgeBest

But I am sure they will deliver again

AaBforever

@E L What do you expect we will hear on fridag 13.?

GeorgeBest

Jan always points out Genmabs abilities to combine bispecific antibodies via robotics. Any idea why other Pharma companies can‘t copy?

GeorgeBest

He says they can produce thousands of samples in the same time as competitors produce a handful!

Bulder

Hopefully an assessment of the quality of efficacy. That's where I'm a little sceptic maybe. But we'll also soon see assessments from the medical world. Looking forward to that.

Bulder

I'm not worried of safety at all.